Nanomedicine News

RSS

FDA Grants Fast Track Status for Celator’s CPX-351 to Treat Elderly Patients with Secondary AML

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML).

21 Jan 2015

New, Wearable Nanowire Sensor Monitors Electrophysiological Signals

Researchers from North Carolina State University have developed a new, wearable sensor that uses silver nanowires to monitor electrophysiological signals, such as electrocardiography (EKG) or electromyography (EMG).

21 Jan 2015

Newly Designed Nanoparticle Can Be Detected By Six Medical Imaging Techniques

It's technology so advanced that the machine capable of using it doesn't yet exist.

21 Jan 2015

MIT Researchers Develop Novel Approach for Nanoscale Resolution Microscopy of Large Biological Samples

Researchers from MIT have successfully discovered a technique to physically magnify tissue samples by implanting them in a polymer, which swells on addition with water to enable high-resolution images. Since the late 1500s when the first microscope was invented, scientists have been devising ways to study preserved tissues and cells in a better manner.

From Massachusetts Institute of Technology 20 Jan 2015

Tiny Microfluidic Device Helps Analyze Behavior of Blood from Sickle Cell Disease Patients

Patients with sickle cell disease often suffer from painful attacks known as vaso-occlusive crises, during which their sickle-shaped blood cells get stuck in tiny capillaries, depriving tissues of needed oxygen. Blood transfusions can sometimes prevent such attacks, but there are currently no good ways to predict when a vaso-occlusive crisis, which can last for several days, is imminent.

From Massachusetts Institute of Technology 20 Jan 2015

Cerulean’s CRLX10 Nanoparticle-Drug Conjugate Phase 1b/2 Data Presented at ASCO 2015 Symposium

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that preclinical data and initial clinical data from a Phase 1b/2 investigator-sponsored trial of CRLX101 in combination with chemoradiotherapy in non-metastatic rectal cancer was presented at the ASCO 2015 Gastrointestinal Cancers Symposium held January 15-17, 2015.

20 Jan 2015

Vicus Presents Two Combination Studies on VT-122 at 2015 Gastrointestinal Cancers Symposium

Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, today announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both studies were presented today at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif.

19 Jan 2015

Two ‘Parent’ Nanoparticles Method Holds Promise for More Efficient Medical Treatments

More efficient medical treatments could be developed thanks to a new method for triggering the rearrangement of chemical particles.

19 Jan 2015

Tumor Microenvironment Could Play a Big Role in Nanoparticle-Based Cancer Therapy

Nanoparticle drugs--tiny containers packed with medicine and with the potential to be shipped straight to tumors--were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall survival rates for cancer patients very much. Scientists at the University of North Carolina at Chapel Hill now think that failure may have less to do with the drugs and tumors than it does the tumor's immediate surroundings.

14 Jan 2015

New Data on Dicerna’s DsiRNA Therapeutics Targeting MYC, β-Catenin Oncogenes Presented at AACR Meeting

Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced the presentation of new preclinical data on its Dicer substrate short interfering RNA (DsiRNA) therapeutics targeting MYC and â-catenin (CTNNB1) oncogenes in models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC).

13 Jan 2015

Nanomedicine News

FDA Grants Fast Track Status for Celator’s CPX-351 to Treat Elderly Patients with Secondary AML

New, Wearable Nanowire Sensor Monitors Electrophysiological Signals

Newly Designed Nanoparticle Can Be Detected By Six Medical Imaging Techniques

MIT Researchers Develop Novel Approach for Nanoscale Resolution Microscopy of Large Biological Samples

Tiny Microfluidic Device Helps Analyze Behavior of Blood from Sickle Cell Disease Patients

Cerulean’s CRLX10 Nanoparticle-Drug Conjugate Phase 1b/2 Data Presented at ASCO 2015 Symposium

Vicus Presents Two Combination Studies on VT-122 at 2015 Gastrointestinal Cancers Symposium

Two ‘Parent’ Nanoparticles Method Holds Promise for More Efficient Medical Treatments

Tumor Microenvironment Could Play a Big Role in Nanoparticle-Based Cancer Therapy

New Data on Dicerna’s DsiRNA Therapeutics Targeting MYC, β-Catenin Oncogenes Presented at AACR Meeting

Combining Nanofluids and Turbulators for Sustainable Energy

Enhancing Material Properties through Nanotube Encapsulation

Brain-Inspired Nano-Tech Promises New Era for Electronics

Breakthrough in 2D Material Growth Opens Doors to Cleaner Energy and Next-Generation Technology

Sustainable Carbon Nanomaterial Gii Set to Transform Energy Storage in Internet of Things Devices

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials